Needham & Company
-
Needham & Company Downgrades Pharmacyclics (PCYC) to Hold; Taking Some Off The Table
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Ibrutinib Continues to Demonstrate Impressive Efficacy/Safety
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); 2012 Preview - PCI-32765 Transitioning to Phase 3
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); ASH Meeting Review; PCI-32765 Continues to Impress; Phase 3 Trials on Track for 2012
-
Needham & Company Assumes Coverage on Pharmacyclics (PCYC) at Buy; Review and ASH Meeting Preview
-
Needham & Company Maintains a 'Buy' on Pharmacyclics (PCYC); ASCO Mtg Presentation Shows Continued Robust Btk PCI-32765 Activity in CLL/SLL
-
Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
-
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Believe Shares Move Higher in Near-Term
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); Updated Data for Btk Inhibitor PCI-32765 Support Comprehensive Program
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); ASH Meeting Data for Btk Inhibitor PCI-32765 Support the Company’s Plans
-
2010 ASCO Meeting Preview - Needham & Co Highlights ArQule (ARQL), Celldex (CLDX), Pharmacyclics (PCYC), and Seattle Genetics (SGEN)
-
Needham & Company Reiterates a 'Buy' on Pharmacyclics (PCYC); FY3Q10 Review/Early FY4Q10 Preview
-
Needham & Company Starts Pharmacyclics (PCYC) at Buy

